Indeed, upon investigation of all prostate data sets, it appears that IKBKE is amplified in CRPC (27.14%; 19/70 cases) compared to prostate adenocarcinoma (1.74%; 82/4712 cases) and normal prostate (0%; 0/313 cases) (Supplementary Figure S4A). Here, IKBKE is linked to prostate adenocarcinoma.